We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
-6.02%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$302M
(+40%)
Cap. Flow
+$392M
Cap. Flow
% of AUM
37.44%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
117
New
33
Increased
29
Reduced
19
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$17.7M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$17.6M |
| 3 |
NUVL
Nuvalent
NUVL
|
+$13.7M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$11.3M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$8.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arvinas
ARVN
|
+$12.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$11.5M |
| 3 |
Spyre Therapeutics
SYRE
|
+$7.13M |
| 4 |
Arrowhead Research
ARWR
|
+$5.64M |
| 5 |
SLNO
Soleno Therapeutics
SLNO
|
+$3.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.37% |
| 2 | Financials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
76
Abivax
ABVX
$11.5B
| $1.25M | 0.12% |
+200,000
| New | +$1.35M |
|
77
Olema Pharmaceuticals
OLMA
$991M
| $1.22M | 0.12% |
+325,000
| New | +$1.63M |
|
78
NextCure
NXTC
$22M
| $1.11M | 0.11% |
191,883
| – | – |
|
79
MeiraGTx Holdings
MGTX
$1.13B
| $1.02M | 0.1% |
+150,000
| New | +$1.01M |
|
80
Vaxcyte
PCVX
$8.01B
| $944K | 0.09% |
25,000
| – | – |
|
81
Viking Therapeutics
VKTX
$4.22B
| $604K | 0.06% |
+25,000
| New | +$790K |
|
82
Sutro Biopharma
STRO
$374M
| $490K | 0.05% |
+75,272
| New | +$1.19M |
|
83
Context Therapeutics
CNTX
$56.6M
| $404K | 0.04% |
660,589
-354,751
| -35% | -$309K |
|
84
Black Diamond Therapeutics
BDTX
$104M
| $388K | 0.04% |
250,000
-309,163
| -55% | -$648K |
|
|
RADX
85
Radiopharm Theranostics
RADX
$33.7M
| $311K | 0.03% |
64,600
-91,571
| -59% | -$476K |
|
86
Zura Bio
ZURA
$500M
| $288K | 0.03% |
223,335
| – | – |
|
87
Compass Therapeutics
CMPX
$364M
| $249K | 0.02% |
+130,807
| New | +$348K |
|
88
Ovid Therapeutics
OVID
$431M
| $208K | 0.02% |
+667,516
| New | +$410K |
|
|
RPTX
89
DELISTED
Repare Therapeutics
RPTX
| $197K | 0.02% |
200,000
+100,000
| +100% | +$121K |
|
|
ADGM
90
Adagio Medical Holdings
ADGM
$11.3M
| $170K | 0.02% |
213,235
| – | – |
|
91
Omeros
OMER
$697M
| $81.9K | 0.01% |
9,958
| – | – |
|
|
ALLK
92
DELISTED
Allakos
ALLK
| $56.9K | 0.01% |
+250,000
| New | +$113K |
|
93
Q32 Bio
QTTB
$346M
| $45.8K | ﹤0.01% |
27,777
| – | – |
|
94
Rocket Pharmaceuticals Warrant
RCKTW
$320K
| $3.52K | ﹤0.01% |
75,000
| – | – |
|
|
IMTXW
95
DELISTED
Immatics N.V. Warrants
IMTXW
| $2.96K | ﹤0.01% |
187,204
| – | – |
|
|
APLS
96
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-50,000
| Closed | -$1.6M |
|
|
97
Arvinas
ARVN
$517M
| – | – |
-630,000
| Closed | -$12.1M |
|
|
98
Arrowhead Research
ARWR
$10.1B
| – | – |
-300,000
| Closed | -$5.64M |
|
99
PUT
Biomea Fusion
BMEA
$94.7M
| – | – |
-150,000
| Closed | -$582K |
|
100
CG Oncology
CGON
$6.19B
| – | – |
-100,000
| Closed | -$2.87M |
|
Similar funds
FM
1SB
HCL
OCM
MWA
AF
NFG
HC
Affinity Asset Advisors's Q1 2025 Portfolio in Review
As of Q1 2025, Affinity Asset Advisors held 117 positions worth $1.05B, up 40% from $746M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Affinity Asset Advisors deployed $392M of net new capital in Q1 2025, opening 33 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 78% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $11.5M trimmed.
- Affinity Asset Advisors's largest Q1 2025 buy was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
- Affinity Asset Advisors added most to Travere Therapeutics in Q1 2025, an estimated $17.7M increase.
- Affinity Asset Advisors's biggest Q1 2025 reduction was Crinetics Pharmaceuticals, cutting an estimated $11.5M.
- Affinity Asset Advisors fully exited Arvinas in Q1 2025, selling an estimated $12.1M.
- Affinity Asset Advisors's ten largest holdings make up 55% of its $1.05B portfolio in Q1 2025.
- Affinity Asset Advisors opened 33 new positions and closed 19 in Q1 2025.
- Affinity Asset Advisors's portfolio value rose 40% quarter-over-quarter to $1.05B.
Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.